US/UK/Canada

Share

Contacts

  • Michael-Robin Witt

    CEO


    http://www.gabather.com
    • Pick a time period -
    Tags ( Active)

    Gabather AB presents preclinical and clinical data of the Lead Drug Candidate, GT-002, at the American Society for Neurosciences (AfN) meeting in Chicago.

    Gabather AB announces that today the company has a poster presentation summarizing the preclinical and clinical data of GT-002 at the AfN meeting in Chicago. The meeting is the biggest scientific meeting within Neurosciences with more than 26 500 international participants. The presentation includes the preclinical data accumulated during the last years as well as clinical data from the previous phase Ia study in healthy volunteers that was finalized in the second quarter of 2019 (Single Ascending Dose study, SAD). ”We are both proud and happy to present our data and research at this

    Gabather AB expands intellectual property portfolio related to the clinical candidate GT-002

    Gabather AB is pleased to announce a further advance in its intellectual property portfolio.  Gabather’s international Patent Cooperation Treaty (PCT) patent application, submitted in December 2017, related to the improved synthesis process for the large-scale manufacture of triazoloquinazolinones, including its GT-002 clinical drug candidate as WO 2019/123011. The application will next enter the PCT National Phases undergoing examination in individual countries in the EU as well as the USA, India, Japan and China . The filing of PCT national phase patent applications is due by July 2020.

    Gabather has completed toxicological studies

    Gabather AB has successfully completed the regulatory GLP toxicology studies with GT-002 in rodent and non-rodent animal models. The compound was generally safe and well tolerated in repeated dose administrations for 28 days in animals at dose levels that are expected to exceed a therapeutically relevant dose. Furthermore, safety pharmacology was without any remarks, and GT-002 showed no negative cardiovascular treatment-related effects, which are important safety features for further clinical development of GT-002. "These results support moving forward into the clinic in the near future

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe